ライフサイエンスコーパス: radioimmunotherapy

1 onitor the therapeutic effect of pretargeted radioimmunotherapy.

2 harmaceuticals; 37.9% did not treat NHL with radioimmunotherapy.

3 r institution accepted Medicare patients for radioimmunotherapy.

4 ne for a more informed design of combination radioimmunotherapy.

5 e myeloid leukaemia 5 months after receiving radioimmunotherapy.

6 tial to be more effective than standard-dose radioimmunotherapy.

7 n tumors typically drops significantly after radioimmunotherapy.

8 ng the response of non-Hodgkin's lymphoma to radioimmunotherapy.

9 ease toxicity of subsequent (131)I-rituximab radioimmunotherapy.

10 before radioimmunotherapy and at 12 wk after radioimmunotherapy.

11 brane antigen, has potential as an agent for radioimmunotherapy.

12 , such as with immunoSPECT and immunoPET, or radioimmunotherapy.

13 L) after treatment with ibritumomab tiuxetan radioimmunotherapy.

14 -Fc H310A/H435Q as a promising candidate for radioimmunotherapy.

15 NHL and 1.9 years (range, 0.4 to 6.3) after radioimmunotherapy.

16 ith multistep immune targeting approaches to radioimmunotherapy.

17 phoma has led to a resurgence of interest in radioimmunotherapy.

18 ionuclides, as currently practiced in cancer radioimmunotherapy.

19 rter residence time that limits their use in radioimmunotherapy.

20 ecules can be used as effective vehicles for radioimmunotherapy.

21 xamined in patients with lymphoma treated by radioimmunotherapy.

22 3, and J591) and their potential utility for radioimmunotherapy.

23 targeting may be involved in the success of radioimmunotherapy.

24 ffer advantages compared with antibody-based radioimmunotherapy.

25 vere during CHOP chemotherapy than following radioimmunotherapy.

26 arted induction treatment; 57 (80%) received radioimmunotherapy.

27 Analyses included only patients who received radioimmunotherapy.

28 ive of improved PFS after (131)I-tositumomab radioimmunotherapy.

29 he clinically emerging method of pretargeted radioimmunotherapy.

30 cells: targeted nanospheres and pretargeted radioimmunotherapy.

31 or dose than is possible with nonpretargeted radioimmunotherapy.

32 cute leukemias administered externally or as radioimmunotherapy.

33 with antibody drug conjugates, and dosing in radioimmunotherapy.

34 Bone marrow is usually dose-limiting for radioimmunotherapy.

35 linical biodistribution studies and clinical radioimmunotherapies.

36 was performed on 13 patients at 24 wk after radioimmunotherapy, 12 of whom did not receive interval

37 diagnosed with tMDS/tAML prior to receiving radioimmunotherapy; 2 (8%) had no pathologic or clinical

38 108 lesions evaluated at 12 and 24 wk after radioimmunotherapy, 49 resolved at 12 wk and remained re

39 d antibody combinations is crucial to making radioimmunotherapy a standard therapeutic modality.

40 Radioimmunotherapy, a novel way of delivering systemic r

41 6 received autologous HCT 3 d after (211)At-radioimmunotherapy, after lymph node and bone marrow bio

42 oal of this work was to determine an optimal radioimmunotherapy agent for further development against

43 p53-negative tumor-bearing mice treated with radioimmunotherapy alone or combined with cisplatin show

44 HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in combination with cisplati

45 ately 30% of its maximum tolerated dose, and radioimmunotherapy alone, at its maximum tolerated dose,

46 New technologies, such as pretargeted radioimmunotherapy, also hold promise by reducing toxici

47 ty-six patients received full-radiation-dose radioimmunotherapy and 12 received attenuated doses beca

48 0) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12 wk after radioimmunotherapy

49 greatly enhanced the therapeutic efficacy of radioimmunotherapy and diminished its toxicities.

50 -PD-L1 antibody for radionuclide imaging and radioimmunotherapy and highlight a new opportunity to op

51 In this study, we used EGFR as a target for radioimmunotherapy and hypothesized that EGFR-directed r

52 Radioimmunotherapy and nuclear imaging (immuno-PET/SPECT

53 Pretargeting provides an alternative radioimmunotherapy and nuclear imaging strategy by overc

54 ysplastic syndrome 28 months after receiving radioimmunotherapy and one patient developed acute myelo

55 t predosing with unlabeled veltuzumab had on radioimmunotherapy and PT-RAIT targeting.

56 , and increased apoptosis were observed with radioimmunotherapy and the combination therapy.

57 vivo purging with rituximab, the utility of radioimmunotherapy and, finally, the evolving strategy o

58 ed systems, lessons learned from pretargeted radioimmunotherapy, and important considerations for har

59 ed immunotherapy with monoclonal antibodies, radioimmunotherapy, and T-cell therapies.

60 receiving radionuclide therapy, particularly radioimmunotherapy, and the relatively long pathlength o

61 pretargeted radioimmunotherapy (PT-RAIT) or radioimmunotherapy, and tumor growth was monitored.

62 hese larger formats may be more suitable for radioimmunotherapy applications, evidenced by the precli

63 ent option, the responses of solid tumors to radioimmunotherapy are discouraging.

64 ive allogeneic transplantation and high-dose radioimmunotherapy are topics of ongoing investigation.

65 The 12-wk overall response rate to radioimmunotherapy based on IWC was 42% (14/33); complet

66 als of nonmyeloablative transplantation with radioimmunotherapy-based conditioning.

67 toxicity is highly unlikely in standard dose radioimmunotherapy but should be considered a potential

68 umor AD to arterial wall AD were greater for radioimmunotherapy by a factor of 1.9-4.0.

69 es could potentially play a valuable role in radioimmunotherapy by more stably encapsulating radionuc

70 ates the opinions and patterns of the use of radioimmunotherapy by nuclear physicians, affiliated res

71 the potential for improving the efficacy of radioimmunotherapy by targeting other NHL cell surface a

72 ctivity retained in the body after high-dose radioimmunotherapy can damage PBSCs if they are transfus

73 otherapy and hypothesized that EGFR-directed radioimmunotherapy can deliver a continuous lethal radia

74 Radioimmunotherapy can effectively treat leptomeningeal

75 re eradicated in mice treated with anti-EGFR radioimmunotherapy combined with chemotherapy and PARP i

76 Radioimmunotherapy combines biologic and radiolytic mech

77 n are comparable to doses reported for other radioimmunotherapy compounds.

78 The therapeutic effect of radioimmunotherapy depends on the distribution of the ab

79 Here, we address the question of radioimmunotherapy efficacy in MM minimal residual disea

80 y (mAb; CA12.10C12) protein dose for (211)At-radioimmunotherapy, extending the analysis to include in

81 valuate and optimize various intraperitoneal radioimmunotherapies for micrometastatic tumors.

82 lenge, rendering (225)Ac@GNTs candidates for radioimmunotherapy for delivery of (225)Ac(3+) ions at h

83 nt the efficacy and decrease the toxicity of radioimmunotherapy for disseminated murine leukemia.

84 le and 13 female; median age, 64 y) received radioimmunotherapy for NHL (20 received (90)Y-ibritumoma

85 Responders who did not administer radioimmunotherapy for NHL thought it took too much time

86 tant role for subgroups in the perception of radioimmunotherapy for NHL.

87 Radioimmunotherapy for non-Hodgkin's lymphoma often resu

88 of targeted monoclonal antibody therapy and radioimmunotherapy for orbital and adnexal non-Hodgkin's

89 antibody 8H9 has been successfully used for radioimmunotherapy for patients with B7-H3(+) tumors.

90 etry suggested a time interval of 13 d after radioimmunotherapy for PBSC infusion.

91 n lymphoma patients after (131)I-tositumomab radioimmunotherapy for potential use in treatment planni

92 viously treated patients, and 4.6 years from radioimmunotherapy for previously untreated patients.

93 The success of radioimmunotherapy for solid tumors remains elusive due

94 mbination therapies using systemic anti-EGFR radioimmunotherapy for the treatment of recurrent and me

95 eview will present the latest information on radioimmunotherapy for treatment of hematologic malignan

96 c information useful for titrating doses for radioimmunotherapy, for patient risk stratification and

97 m baseline in 244 target lesions 12 wk after radioimmunotherapy (from 6.51+/-4.05 to 3.94+/-4.41; P<0

98 Standard doses of radioimmunotherapy given as a conditioning regimen for h

99 em-cell transplant or myeloablative doses of radioimmunotherapy given in conjunction with stem-cell s

100 owed delayed tumor growth in the pretargeted radioimmunotherapy group, corresponding with their prolo

101 d consolidation as a possible indication for radioimmunotherapy had significantly fewer concerns abou

102 ividuals who perceived a negative future for radioimmunotherapy had significantly more concerns about

103 The safety and efficacy of radioimmunotherapy has been demonstrated for patients wi

104 The use of radioimmunotherapy has been evaluated in the treatment o

105 Radioimmunotherapy has been successfully used in the tre

106 (I)-labeled monoclonal antibodies (MAbs) for radioimmunotherapy has been the rapid diffusion of iodot

107 Radioimmunotherapy has emerged as one of the most promis

108 Because radioimmunotherapy has resulted in long-term survival of

109 alpha-Particle emitter (213)Bi-based radioimmunotherapy has shown efficacy in a variety of me

110 therapies, both unconjugated antibodies and radioimmunotherapy, have had a significant impact on the

111 treated at our centers with either high-dose radioimmunotherapy (HD-RIT) using 131I-anti-CD20 (n = 27

112 ioimmunotherapy predicted a higher growth of radioimmunotherapy if they could administer it in their

113 We explored i.p. radioimmunotherapy in a mouse model of human ovarian can

114 an intravenous fractionated regimen of alpha-radioimmunotherapy in a subcutaneous tumor model in mice

115 In this first preclinical study of anti-EGFR radioimmunotherapy in breast cancer, we found that anti-

116 n vivo purging with rituximab and the use of radioimmunotherapy in conditioning regimens may further

117 ficacy with the combination of cetuximab and radioimmunotherapy in CRC, which could potentially trans

118 role of kinetic and transport parameters of radioimmunotherapy in maximizing the therapeutic ratio,

119 atuzumab tetraxetan ((90)Y-DOTA-epratuzumab) radioimmunotherapy in refractory or relapsed CD22-positi

120 at have paved the way to an understanding of radioimmunotherapy in solid tumors.

121 atients with non-Hodgkin lymphoma (NHL) with radioimmunotherapy in the last 24 mo.

122 erred patients with non-Hodgkin lymphoma for radioimmunotherapy in the last 24 mo.

123 nical trials and reinvigorate enthusiasm for radioimmunotherapy in the treatment of malignancies, par

124 and medical oncologists about CD20-directed radioimmunotherapy in the United States.

125 on make tomoregulin an attractive target for radioimmunotherapy, in which tomoregulin-specific antibo

126 scientific concerns, barriers to the use of radioimmunotherapy included difficulty in referral, perc

127 White blood cell count analysis after alpha-radioimmunotherapy indicated bone marrow recovery for th

128 Radioimmunotherapy infusion was overall well tolerated.

129 The increased uptake of radioimmunotherapy into the tumor resulted in >400% incr

130 w (RM) is often the primary organ at risk in radioimmunotherapy; irradiation of marrow may induce sho

131 Radioimmunotherapy is an effective treatment for non-Hod

132 Radioimmunotherapy is approved by the Food and Drug Admi

133 Radioimmunotherapy is considered to have great potential

134 Anti-CD20 radioimmunotherapy is effective in patients who have had

135 Radioimmunotherapy is emerging as an attractive alternat

136 py in breast cancer, we found that anti-EGFR radioimmunotherapy is safe and that TNBC orthotopic tumo

137 ubsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown.

138 table response rates have been observed when radioimmunotherapy is used as front-line treatment in pa

139 Thus, Pretarget radioimmunotherapy is very promising and could represent

140 (90)Y-DOTA-epratuzumab radioimmunotherapy is well tolerated.

141 For the growth of radioimmunotherapy, it appears crucial not only to demon

142 The amount of radioactivity for radioimmunotherapy may be determined by several methods,

143 Cytogenetic testing before treatment with radioimmunotherapy may identify existing chromosomal abn

144 In radioimmunotherapy, myelotoxicity due to bone marrow rad

145 In patients who progress after radioimmunotherapy, new sites of disease commonly develo

146 t of these bsRICs for dual-receptor-targeted radioimmunotherapy of BC coexpressing HER2 and EGFR, inc

147 Radioimmunotherapy of cancer with radiolabeled antibodie

148 which has shown promise for PET imaging and radioimmunotherapy of cancer.

149 mply that the optimal strategy for A33-based radioimmunotherapy of colon cancer will consist of a mul

150 Whereas radioimmunotherapy of hematologic malignancies has evolv

151 subunit, as a favorable target for systemic radioimmunotherapy of HL.

152 the absorbed dose (AD) to the artery wall in radioimmunotherapy of NHL is of potential concern for de

153 OTA chelate represents an improved agent for radioimmunotherapy of non-Hodgkin's lymphoma, with an in

154 adiolabeled mAb-PAM4 for nuclear imaging and radioimmunotherapy of pancreatic carcinoma.

155 clearly validate tomoregulin as a target for radioimmunotherapy of prostate cancer.

156 essed molecule, tomoregulin, as a target for radioimmunotherapy of prostate cancer.

157 Success in the radioimmunotherapy of solid tumors has lagged because of

158 Radioimmunotherapy of solid tumors using antibody-target

159 h the radiobiologic paradigms for successful radioimmunotherapy of solid tumors.

160 g proteins may be superior to antibodies for radioimmunotherapy of solid tumors.

161 tibody that pretargeted (90)Y-hapten-peptide radioimmunotherapy or a directly radiolabeled, humanized

162 lymphoma and can be used in combination with radioimmunotherapy or standard chemotherapy for a more d

163 safety during infusions and regularly after radioimmunotherapy over a 6-month period.

164 thought it took too much time to administer radioimmunotherapy (P < 0.01) and had concerns about the

165 own practices if they referred patients for radioimmunotherapy (P < 0.01).

166 tion process (P < 0.05) and the high cost of radioimmunotherapy (P < 0.05).

167 0.01), regardless of response at 12 wk after radioimmunotherapy (P<or=0.02).

168 Finally, the 3D methods were applied to a radioimmunotherapy patient, and the mean tumor absorbed

169 efficacy and safety of anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metast

170 Initial response assessments 12 wk after radioimmunotherapy predict longer-term response.

171 with a positive outlook about the future of radioimmunotherapy predicted a higher growth of radioimm

172 We now show the superiority of pretargeted radioimmunotherapy (PRIT) compared with conventional rad

173 Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable ef

174 Pretargeted radioimmunotherapy (PRIT) has the potential to increase

175 Pretargeted radioimmunotherapy (PRIT) is designed to enhance the dir

176 recently reported a novel 3-step pretargeted radioimmunotherapy (PRIT) strategy based on a glycoprote

177 Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgk

178 Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (A

179 We describe the use of pretargeted radioimmunotherapy (PRIT) using an anti-murine CD45 anti

180 Pretargeted radioimmunotherapy (PRIT) using streptavidin (SA)-conjug

181 Pretargeted radioimmunotherapy (PRIT) with the beta-emitting radionu

182 e therapy, can potentially be used to design radioimmunotherapy protocols to improve efficacy.

183 ies alone or in combination with pretargeted radioimmunotherapy (PT-RAIT) or radioimmunotherapy, and

184 tetraacetic acid-di-HSG-peptide (pretargeted radioimmunotherapy [PT-RAIT]).

185 safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed

186 d marrow absorbed dose in patients receiving radioimmunotherapy (RAIT) has not been highly predictive

187 improved therapeutic index with pretargeted radioimmunotherapy (RAIT) using a DNL-constructed tri-Fa

188 w that anti-GPA33 DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal

189 The tositumomab/(131)I-tositumomab radioimmunotherapy regimen is administered as a dosimetr

190 t3 ligand were also measured to evaluate the radioimmunotherapy-related myelotoxicity.

191 Radioimmunotherapy represents a potential option as cons

192 s the most current allogeneic HCT data using radioimmunotherapy (RIT) and focuses on recent trials in

193 Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation

194 The usefulness of radioimmunotherapy (RIT) for infectious diseases was rec

195 The efficacy of radioimmunotherapy (RIT) for patients with relapsed non-

196 Radioimmunotherapy (RIT) for pediatric tumors remains in

197 was 6 years from diagnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients

198 Radioimmunotherapy (RIT) for treatment of hematologic ma

199 e treatment of non-Hodgkin's lymphoma (NHL), radioimmunotherapy (RIT) has finally come of age as a ne

200 or groups as potential yttrium chelators for radioimmunotherapy (RIT) have been prepared via a conven

201 ry radiosensitive, but the potential role of radioimmunotherapy (RIT) in the management of plasmacyto

202 (375 mg/m(2)) and proceeded to fractionated radioimmunotherapy (RIT) only if a repeat BM biopsy demo

203 Radioimmunotherapy (RIT) options for T-cell non-Hodgkin

204 Radioimmunotherapy (RIT) prolongs the survival of mice i

205 d a conditioning regimen employing anti-CD45 radioimmunotherapy (RIT) replacing total body irradiatio

206 Radioimmunotherapy (RIT) using (131)I-tositumomab has be

207 anti-DR) antibodies (Abs) and of pretargeted radioimmunotherapy (RIT) using Ab-streptavidin (SA) conj

208 Pretargeted radioimmunotherapy (RIT) using CC49 fusion protein, comp

209 Radioimmunotherapy (RIT) using monoclonal antibodies lab

210 Pretargeted radioimmunotherapy (RIT) using streptavidin (sAv)-conjug

211 ium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for rela

212 Radioimmunotherapy (RIT) with alpha-emitting radionuclid

213 One novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal

214 Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled

215 gh metastatic breast cancer is responsive to radioimmunotherapy (RIT), a systemic targeted radiation

216 targeting and tumor control by CD20-directed radioimmunotherapy (RIT), but had no impact on targeting

217 ed with either external beam radiotherapy or radioimmunotherapy (RIT), which joins the selectivity of

218 (CMIT) with yttrium (90)Y-DOTA-peptide-Lym-1 radioimmunotherapy (RIT).

219 11)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT).

220 vasive cancer radioimmunodetection (RID) and radioimmunotherapy (RIT).

221 on with tositumomab/iodine I-131 tositumomab radioimmunotherapy (RIT).

222 radiolabeled bivalent antibody (conventional radioimmunotherapy [RIT]).

223 An antibody-targeted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand t

224 als are currently underway to further define radioimmunotherapy's role in the treatment of lymphomas.

225 In contrast, radioimmunotherapy should still be efficacious in metast

226 rt prolongs remission and consolidation with radioimmunotherapy shows promise.

227 d with monotherapy, combining cetuximab with radioimmunotherapy significantly and synergistically red

228 Radioimmunotherapy studies in p53-positive HCT116 tumor-

229 In addition, a radioimmunotherapy study, using the anti-uPAR antibodies

230 After radioimmunotherapy, SUVlean max was lower for responders

231 inal half-life and serum clearance suited to radioimmunotherapy (T1/2beta, 100.24 +/- 20.92 h, and cl

232 d comparative assessments using conventional radioimmunotherapy targeting CD20, CD22, and HLA-DR on h

233 alpha-radioimmunotherapy targeting CD45 may substitute for tot

234 meters and may be particularly effective for radioimmunotherapy targeting minimal residual disease (M

235 Radioimmunotherapy, targeting the CD20 antigen, in B-cel

236 onjugates are better candidates for targeted radioimmunotherapy than are antibodies targeting PSMA(in

237 In high-dose radioimmunotherapy, the importance of patient-specific d

238 derable success in improving the efficacy of radioimmunotherapy, the pretargeting strategy remains un

239 dies targeting lymphoma-associated antigens, radioimmunotherapy, therapeutic vaccination and allogene

240 zed that selective ablation of T cells using radioimmunotherapy together with postgrafting immunosupp

241 Radioimmunotherapy toxicity consisted of grade 3-4 throm

242 e tumor absorbed radiation doses in STI571 + radioimmunotherapy-treated mice compared with PBS + radi

243 munotherapy-treated mice compared with PBS + radioimmunotherapy-treated mice.

244 reason for the growth arrest of the STI571 + radioimmunotherapy-treated tumors.

245 atients in the phase I trial of intra-Ommaya radioimmunotherapy using (131)I-3F8.

246 Myeloablative radioimmunotherapy using (131)I-tositumomab (anti-CD20)

247 Therefore, EGFR-directed radioimmunotherapy using (90)Y-Y-CHX-A''-DTPA-cetuximab

248 Early results from radioimmunotherapy using 8H9 have shown promise in patie

249 unotherapy (PRIT) compared with conventional radioimmunotherapy using a recombinant tetravalent singl

250 Radioimmunotherapy using alpha-emitters such as (213)Bi,

251 Despite the promise of radioimmunotherapy using anti-CD20 antibodies (Ab) for t

252 These data suggest that conventional radioimmunotherapy using anti-CD20, anti-HLA-DR, or anti

253 assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 (90)Y-epratuzumab tet

254 Radioimmunotherapy using targeted monoclonal antibodies

255 ated the preclinical efficacy of combination radioimmunotherapy, using a humanized (131)I-labeled ant

256 bolic activity was assessed before and after radioimmunotherapy visually and quantitatively by lean m

257 Radioimmunotherapy was generally viewed positively by re

258 Radioimmunotherapy was generally viewed positively by th

259 n percentage decline in platelet count after radioimmunotherapy was greater in the (90)Y-ibritumomab

260 Radioimmunotherapy was performed 10 d after 5T33 cell en

261 ed survey with 13 broad questions related to radioimmunotherapy was sent electronically to 13,221 Soc

262 various sizes after intraperitoneal (211)At-radioimmunotherapy, we used an in-house-developed Monte

263 emarkable improvements in tumor responses to radioimmunotherapy were discovered after the inclusion o

264 SPECT to monitor the response to pretargeted radioimmunotherapy were examined.

265 tracer infusion of (131)I-tositumomab before radioimmunotherapy were reviewed.

266 this study was to determine the efficacy of radioimmunotherapy when using (90)Y-labeled cetuximab an

267 trials have shown the promise of pretargeted radioimmunotherapy, which leverages the specificity of a

268 Clinical radioimmunotherapies with anti-CD20 monoclonal antibodie

269 umor-to-red marrow dose ratio was higher for radioimmunotherapy with (177)Lu-cG250 than for radioimmu

270 predict absorbed doses and myelotoxicity of radioimmunotherapy with (177)Lu-cG250.

271 vity of (111)In-cG250 (185 MBq), followed by radioimmunotherapy with (177)Lu-cG250.

272 s to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG250.

273 cts on tumor growth after fractionated alpha-radioimmunotherapy with (211)At-MX35-F(ab')2 was strong

274 cts on tumor growth after fractionated alpha-radioimmunotherapy with (211)At-MX35-F(ab')2 was strong

275 Radioimmunotherapy with (225)Ac-E4G10 was performed in N

276 Radioimmunotherapy with (64)Cu was highly effective in a

277 e examine the role of p53 in the response to radioimmunotherapy with (64)Cu-DOTA-cetuximab in KRAS-mu

278 Radioimmunotherapy with (90)Y ibritumomab tiuxetan is we

279 dioimmunotherapy with (177)Lu-cG250 than for radioimmunotherapy with (90)Y-cG250, indicating that (17

280 INTERPRETATION: Fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan mig

281 Fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan mig

282 Dosimetric projections for radioimmunotherapy with (90)Y-labeled J591 suggested sim

283 used to generate dosimetric projections for radioimmunotherapy with (90)Y-labeled J591.

284 (211)At-anti-CD45 radioimmunotherapy with 0.75 mg mAb/kg efficiently targe

285 Recent data suggest that radioimmunotherapy with 131I-tositumomab or 90Y-ibritumo

286 This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplanta

287 ternal gamma-beam radiation, we investigated radioimmunotherapy with an anti-CD45 mAb labeled with th

288 ation derived from a Cs-137 source, systemic radioimmunotherapy with an I-131-conjugated monoclonal a

289 a dose of 2 mCi/kg Bi, further trials using radioimmunotherapy with Bi for nonmyeloablative HCT seem

290 study demonstrates that dose deescalation of radioimmunotherapy with Bi labeled to anti-CD45 or anti-

291 t (177)Lu has a wider therapeutic window for radioimmunotherapy with cG250 than (90)Y.

292 Although radioimmunotherapy with radiolabeled intact monoclonal a

293 the authors demonstrated that pretransplant radioimmunotherapy with the alpha-emitter bismuth-213 (B

294 R could be treated by dual-receptor-targeted radioimmunotherapy with these bsRICs labeled with the be

295 analysis shows the feasibility of outpatient radioimmunotherapy with tositumomab and (131)I-tositumom

296 oped determining patient releasability after radioimmunotherapy with tositumomab and (131)I-tositumom

297 he limitations of conventional, or one-step, radioimmunotherapy, with initial preclinical and clinica

298 Almost 30% (29.6%) of the responders thought radioimmunotherapy would probably grow and 38.0% thought

299 Seventy-nine (36.6%) responders thought radioimmunotherapy would probably grow in importance, an

300 The optimal antibody mass for radioimmunotherapy would therefore appear to be greater